PART 01: Executive summary • Highlights PART 02: Scope of the report • Market overview • Top-vendor offerings PART 03: Market research methodology • Research methodology • Economic indicators PART 04: Introduction • Key market highlights • Key buying criteria PART 05: Disease overview • Types of myocardial infarction • Pathophysiology • Risk factors • Diagnosis • Management PART 06: Epidemiology and economic burden • Burden of disease PART 07: Pipeline analysis • Canakinumab • MyoCell • MultiStem therapy • CLBS10 • Prochymal • Revascor • CicloMulsion • PP-099 • NP202 • CAP-1002 • Revacept • CSL112 PART 08: Market landscape • Market overview • Market size and forecast • Five forces analysis PART 09: Market segmentation by drug class • Beta blockers • ACE inhibitors • ARBs • Vasodilators • Antithrombotic agents • Thrombolytics • Glycoprotein IIb/IIIa inhibitors • Anti-dyslipidemic drugs • Calcium channel blockers • Analgesics PART 10: Market segmentation by EKG appearance • NSTEMI • STEMI PART 11: Market segmentation by type • Brand-name drugs • Generic drugs PART 12: Geographical segmentation • Global myocardial infarction drugs market segmentation by geography 2015-2020 • Myocardial infarction drugs market in Americas • Myocardial infarction drugs market in EMEA • Myocardial infarction drugs market in APAC PART 13: Market drivers • Increase in older population • Sedentary lifestyle • Rise in obesity • High prevalence of chronic conditions PART 14: Impact of drivers PART 15: Market challenges • Delayed diagnosis • Alternative therapies • Extensive use of generics PART 16: Impact of drivers and challenges PART 17: Market trends • Growing awareness of disease • Strategic alliances • Increased R&D • Prevalent use of stent grafts PART 18: Vendor landscape • Competitive scenario • AstraZeneca • Bayer HealthCare • Eli Lilly • Novartis • Pfizer • Sanofi • Other prominent vendors PART 19: Appendix • List of abbreviations PART 20: Explore Technavio   List of Exhibits Exhibit 01: Product offerings Exhibit 02: Key buying criteria for myocardial infarction drugs Exhibit 03: Pathophysiology of myocardial infarction Exhibit 04: Risk factors of myocardial infarction Exhibit 05: Diagnostic techniques for myocardial infarction Exhibit 06: Treatment options for myocardial infarction Exhibit 07: Projected prevalence of CVDs in US Exhibit 08: Projected economic burden for CVDs in US Exhibit 09: Pipeline portfolio: Myocardial infarction Exhibit 10: Global myocardial infarction drugs market 2015-2020 ($ billions) Exhibit 11: Five forces analysis Exhibit 12: Global myocardial infarction drugs market segmentation by EKG appearance 2015 Exhibit 13: Global myocardial infarction drugs market segmentation by type 2015 Exhibit 14: Global myocardial infarction drugs market segmentation by geography 2015 Exhibit 15: Myocardial infarction drugs market revenue by geography 2015-2020 ($ billions) Exhibit 16: Myocardial infarction drugs market in Americas 2015-2020 ($ billions) Exhibit 17: Myocardial infarction drugs market in EMEA 2015-2020 ($ billions) Exhibit 18: Myocardial infarction drugs market in APAC 2015-2020 ($ billions) Exhibit 19: Global myocardial infarction drugs market: YoY growth and revenue based on geography 2015-2020 Exhibit 20: Impact of drivers Exhibit 21: Impact of drivers and challenges Exhibit 22: AstraZeneca: Business segmentation by revenue 2014 Exhibit 23: AstraZeneca: Cardiovascular and metabolic diseases segment by revenue 2014 Exhibit 24: AstraZeneca: YoY revenue and growth rate of Crestor 2012-2014 ($ billions) Exhibit 25: AstraZeneca: YoY revenue and growth rate of Seloken/Toprol 2012-2014 ($ millions) Exhibit 26: AstraZeneca: YoY revenue and growth rate of Atacand 2012-2014 ($ millions) Exhibit 27: AstraZeneca: YoY revenue and growth rate of Brilinta/Brilique 2012-2014 ($ millions) Exhibit 28: AstraZeneca: Key takeaways Exhibit 29: Bayer HealthCare: YoY revenue and growth rate of Xarelto 2012-2014 ($ millions) Exhibit 30: Bayer HealthCare: YoY revenue and growth rate of Adalat 2012-2014 ($ millions) Exhibit 31: Bayer HealthCare: Key takeaways Exhibit 32: Eli Lilly: YoY revenue and growth rate of Effient (global) 2012-2015 ($ millions) Exhibit 33: Eli Lilly: YoY revenue and growth rate of Effient in US 2012-2015 ($ millions) Exhibit 34: Eli Lilly: YoY revenue and growth rate of Effient in rest of world 2012-2015 ($ millions) Exhibit 35: Eli Lilly: Key takeaways Exhibit 36: Novartis: YoY revenue and growth rate of Diovan 2012-2015 ($ billions) Exhibit 37: Novartis: YoY revenue and growth rate of Exforge 2012-2015 ($ billions) Exhibit 38: Novartis: Key takeaways Exhibit 39: Pfizer: YoY revenue and growth rate of Lipitor 2012-2014 ($ billions) Exhibit 40: Pfizer: YoY revenue and growth rate of Norvasc 2012-2014 ($ billions) Exhibit 41: Pfizer: YoY revenue and growth rate of Fragmin 2012-2014 ($ millions) Exhibit 42: Pfizer: YoY revenue and growth rate of Caduet 2012-2014 ($ millions) Exhibit 43: Pfizer: Key takeaways Exhibit 44: Sanofi: YoY revenue and growth rate of Plavix 2012-2014 ($ billions) Exhibit 45: Sanofi: YoY revenue and growth rate of Lovenox 2012-2014 ($ billions) Exhibit 46: Sanofi: Key takeaways

AstraZeneca, Bayer HealthCare, Eli Lilly, Novartis, Pfizer, Sanofi, advanceCOR, Armaron Bio, Athersys, BioVascular, BMS, Caladrius, Capricor, CSL Behring, GNT Pharma, GSK, Ischemix, Mesoblast, NeuroVive, Osiris Therapeutics, PledPharma, RegeneRx, Teva Pharmaceuticals, TiGenix, US Stem Cell, Ventrix.